Review Article
Volume 4 Issue 1 - 2021
The Causes, Consequences, and Cures of Recurrent External Fungal Infections
Nicholas A Kerna1,2*, John V Flores3,4, Hilary M Holets3,4, Mark H Chen5, Lawrence U Akabike6, Shain Waugh7, Emmanuela Solomon8 and Uzoamaka Nwokorie9
1SMC–Medical Research, Thailand
2First InterHealth Group, Thailand
3Beverly Hills Wellness Surgical Institute, USA
4Orange Partners Surgicenter, USA
5For Your Health, LLC, USA
6Larrico Enterprises, LLC, USA
7Fettle Path, USA
8Obafemi Awolowo University, Nigeria
9University of Washington, USA
*Corresponding Author: Nicholas A Kerna, (mailing address) POB47 Phatphong, Suriwongse Road, Bangkok, Thailand 10500.
Received: November 30, 2020; Published: December 31, 2020




Abstract

Superficial fungal infections affect greater than 20% of the global population. Only a few hundred (of the millions of fungi species) are capable of causing human infections. Moreover, superficial infections respond well to various over-the-counter products. However, resistance to specific anti-fungal medicines is developing. The skin surface is an ideal growth environment for dermatophytes, commonly found around public swimming pools, locker rooms, and showers. Transmission occurs through direct person-to-person contact or indirect contact through the handling of contaminated objects. Immunocompromised patients and those with active illnesses and diseases are at a greater risk for fungal and recurrent fungal infections. An individual’s genetic design may predispose them to specific fungal infections. Also, specific factors, such as cosmetics, body soaps, and other hygiene products, can alter the skin microbiome, predisposing the host to pathologic fungal infestation. This article reviews the etiology of external fungal infections and recurrent infections, considers susceptibility factors, and describes and evaluates currently available treatment options.

Keywords: Azole; Dermatophyte Infection; Immune Response; Mannan; Microbiome; Omics; Polyenes; Resistance; Targeted Sequencing

References

  1. Kim SH., et al. “Epidemiological Characterization of Skin Fungal Infections Between the Years 2006 and 2010 in Korea”. Osong Public Health and Research Perspectives 6 (2015): 341-345. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700767/
  2. One Health: Fungal Pathogens of Humans, Animals, and Plants: Report on an American Academy of Microbiology Colloquium held in Washington, DC (2017). https://www.ncbi.nlm.nih.gov/books/NBK549988/
  3. Hernandez H and Martinez LR. “Relationship of environmental disturbances and the infectious potential of fungi”. Microbiology3 (2018): 233-241. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885008/
  4. Kobayashi GS. “Disease Mechanisms of Fungi”. In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston (1996). https://www.ncbi.nlm.nih.gov/books/NBK8103/
  5. Wiederhold NP. “Antifungal resistance: current trends and future strategies to combat”. Infection and Drug Resistance 10 (2017): 249-259. https://pubmed.ncbi.nlm.nih.gov/28919789/
  6. Elewski BE. “Onychomycosis: pathogenesis, diagnosis, and management”. Clinical Microbiology Reviews 3 (1998): 415-429. https://pubmed.ncbi.nlm.nih.gov/9665975/
  7. Gupta AK., et al. “Fungal Skin Infections”. Pediatrics in Review 1 (2017): 8-22. https://pedsinreview.aappublications.org/content/38/1/8
  8. Kaushik N., et al. “Superficial Fungal Infections”. Primary Care 4 (2015): 501-516. https://accessmedicine.mhmedical.com/content.aspx?bookid=2184&sectionid=165459177
  9. Metin A., et al. “Recurrent candidal intertrigo: challenges and solutions”. Clinical, Cosmetic and Investigational Dermatology 11 (2018): 175-185. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909782/
  10. Martinez-Rossi NM., et al. “Heat Shock Proteins in Dermatophytes: Current Advances and Perspectives”. Current Genomics 2 (2016): 99-111. https://pubmed.ncbi.nlm.nih.gov/27226766/
  11. White TC., et al. “Fungi on the skin: dermatophytes and Malassezia”. Cold Spring Harbor Perspectives in Medicine 8 (2014): a019802. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109575/
  12. Informed Health.org [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. Athlete's foot: Overview (2015). https://www.ncbi.nlm.nih.gov/books/NBK65083/
  13. Richardson MD and Warnock DW. “Fungal Infection: Diagnosis and Management. Wiley (2011). https://www.wiley.com/en-us/Fungal+Infection%3A+Diagnosis+and+Management%2C+4th+Edition-p-9781405170567
  14. Tainwala R and Sharma Y. “Pathogenesis of dermatophytosis”. Indian Journal of Dermatology 3 (2011): 259-261. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132899/
  15. McKeny PT., et al. “Antifungal Antibiotics (2020). https://pubmed.ncbi.nlm.nih.gov/11831475/
  16. Jain A., et al. “Emerging fungal infections among children: A review on its clinical manifestations, diagnosis, and prevention”. Journal of Pharmacy and Bioallied Sciences 4 (2010): 314-320. https://pubmed.ncbi.nlm.nih.gov/21180463/
  17. Dahl MV and Grando SA. “Chronic dermatophytosis: what is special about Trichophyton rubrum?” Advances in Dermatology 9 (1994): 97-109. https://pubmed.ncbi.nlm.nih.gov/8060745/
  18. Dogra S and Uprety S. “The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive?” Indian Dermatology Online Journal 2 (2016): 73-76. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804598/
  19. Institute of Medicine (US) Committee on Emerging Microbial Threats to Health in the 21st Century; Smolinski MS, Hamburg MA, Lederberg J, editors. Microbial Threats to Health: Emergence, Detection, and Response. Washington (DC): National Academies Press (US) (2003).
  20. Blake JS., et al. “An immunoinhibitory cell wall glycoprotein (mannan) from Trichophyton rubrum”. Journal of Investigative Dermatology 5 (1991): 657-661. https://pubmed.ncbi.nlm.nih.gov/2022872/
  21. Calich VLG., et al. “Regulatory T cells in paracoccidioidomycosis”. Virulence1 (2019): 810-821. https://pubmed.ncbi.nlm.nih.gov/30067137/
  22. Nicholson LB. “The immune system”. Essays Biochem3 (2016): 275-301. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091071/
  23. Roussey JA., et al. “Immunoregulation in Fungal Diseases”. Microorganisms4 (2016): 47. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192530/
  24. Lanternier F., et al. “Primary immunodeficiencies underlying fungal infections”. Current Opinion in Pediatrics 6 (2013): 736-747. https://pubmed.ncbi.nlm.nih.gov/24240293/
  25. Klotz SA., et al. “Fungal and parasitic infections of the eye”. Clinical Microbiology Reviews 4 (2000): 662-685. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC88956/
  26. Okada S. “CMCD: Chronic Mucocutaneous Candidiasis Disease”. Nihon Rinsho Meneki Gakkai Kaishi2 (2017): 109-117. https://pubmed.ncbi.nlm.nih.gov/28603201/
  27. Brasch J. “Current knowledge of host response in human tinea”. Mycoses4 (2009): 304-312. https://www.researchgate.net/publication/23998355_Current_knowledge_of_host_response_in_human_tinea
  28. Bragulla HH and Homberger DG. “Structure and functions of keratin proteins in simple, stratified, keratinized and cornified epithelia”. Journal of Anatomy 4 (2009): 516-559. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736122/
  29. Guarner J and Brandt ME. “Histopathologic diagnosis of fungal infections in the 21st century”. Clinical Microbiology Reviews 2 (2011): 247-280. https://pubmed.ncbi.nlm.nih.gov/21482725/
  30. Guarro J., et al. “Developments in fungal taxonomy”. Clinical Microbiology Reviews 3 (1999): 454-500. https://cmr.asm.org/content/12/3/454
  31. Kim JY and Dao H. “Physiology, Integument (2020).
  32. Tsuboi R., et al. “Pathogenesis of superficial mycoses”. Journal of Medical and Veterinary Mycology 1 (1994): 91-104. https://academic.oup.com/mmy/article-abstract/32/Supplement_1/91/944259?redirectedFrom=fulltext
  33. Yang L., et al. “Comparison between gene expression of conidia and germinating phase in Trichophyton rubrum”. Science China Life Sciences 3 (2007): 377-384. https://pubmed.ncbi.nlm.nih.gov/17609895/
  34. Ferreira-Nozawa MS., et al. “The pH signaling transcription factor PacC mediates the growth of Trichophyton rubrum on human nail In vitro”. Medical Mycology 7 (2006): 641-645. https://pubmed.ncbi.nlm.nih.gov/17071558/
  35. Hellgren L and Vincent J. “Lipolytic activity of some dermatophytes”. Journal of Medical Microbiology 1 (1980): 155-157. https://pubmed.ncbi.nlm.nih.gov/7359572/
  36. Das SK and Banerjee AB. “Lipolytic enzymes of Trichophyton rubrum”. Sabouraudia3 (1977): 313-323. https://pubmed.ncbi.nlm.nih.gov/23589/
  37. Dahl MV. “Dermatophytosis and the immune response”. Journal of the American Academy of Dermatology 3-2 (1994): S34-S41. https://pubmed.ncbi.nlm.nih.gov/8077506/
  38. Soll DR. “Mixed Mycotic Infections”. In: Brogden KA, Guthmiller JM, editors. Polymicrobial Diseases”. Washington (DC): ASM Press (2002). https://www.ncbi.nlm.nih.gov/books/NBK2485/
  39. Kany S., et al. “Cytokines in Inflammatory Disease”. International Journal of Molecular Sciences 23 (2019): 6008. https://pubmed.ncbi.nlm.nih.gov/31795299/
  40. Grice EA and Segre JA. “The skin microbiome”. Nature Reviews Microbiology 4 (2011): 244-253. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535073/
  41. Wang Q., et al. “Host and microbiome multi-omics integration: applications and methodologies”. Biophysical Reviews 1 (2019): 55-65. https://pubmed.ncbi.nlm.nih.gov/30627872/
  42. Davidson RM and Epperson LE. “Microbiome Sequencing Methods for Studying Human Diseases”. Methods in Molecular Biology 1706 (2018): 77-90. https://pubmed.ncbi.nlm.nih.gov/29423794/
  43. Grice EA and Segre JA. “The skin microbiome”. Nature Reviews Microbiology 4 (2011): 244-253. https://pubmed.ncbi.nlm.nih.gov/21407241/
  44. Wanke I., et al. “Skin commensals amplify the innate immune response to pathogens by activation of distinct signaling pathways”. Journal of Investigative Dermatology 2 (2011): 382-390. https://www.researchgate.net/publication/47676539_Skin_Commensals_Amplify_the_Innate_Immune_Response_to_Pathogens_by_Activation_of_Distinct_Signaling_Pathways
  45. Dreno B., et al. “Microbiome in healthy skin, update for dermatologists”. Journal of the European Academy of Dermatology and Venereology 12 (2016): 2038-2047. https://pubmed.ncbi.nlm.nih.gov/27735094/
  46. Grice EA., et al. “Topographical and temporal diversity of the human skin microbiome”. Science 5931 (2009): 1190-1192. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805064/
  47. Oh J., et al. “Temporal Stability of the Human Skin Microbiome”. Cell 4 (2016): 854-866. https://www.cell.com/fulltext/S0092-8674(16)30399-3
  48. Bouslimani A., et al. “The impact of skin care products on skin chemistry and microbiome dynamics”. BMC Biology 1 (2019): 47. https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-019-0660-6
  49. Rocha LA., et al. “Changes in hands microbiota associated with skin damage because of hand hygiene procedures on the health care workers”. American Journal of Infection Control 2 (2009): 155-159. https://www.ajicjournal.org/article/S0196-6553(08)00675-5/abstract
  50. Two AM., et al. “The Cutaneous Microbiome and Aspects of Skin Antimicrobial Defense System Resist Acute Treatment with Topical Skin Cleansers”. Journal of Investigative Dermatology 10 (2016): 1950-1954. https://pubmed.ncbi.nlm.nih.gov/27377698/
  51. Blumberg R and Powrie F. “Microbiota, disease, and back to health: a metastable journey”. Science Translational Medicine 137 (2012): 137rv7. https://stm.sciencemag.org/content/4/137/137rv7.full
  52. Stehlikova Z., et al. “Dysbiosis of Skin Microbiota in Psoriatic Patients: Co-occurrence of Fungal and Bacterial Communities”. Frontiers in Microbiology 10 (2019): 438. https://pubmed.ncbi.nlm.nih.gov/30949136/
  53. Liu X., et al. “Characterization of Skin Microbiome in Tinea Pedis”. Indian Journal of Medical Microbiology 4 (2019): 422-427. https://www.researchgate.net/publication/334375350_Characterization_of_Skin_Microbiome_in_Tinea_Pedis
  54. Hay R. “Therapy of Skin, Hair and Nail Fungal Infections”. Journal of Fungi 3 (2018): 99. https://pubmed.ncbi.nlm.nih.gov/30127244/
  55. Sanglard D. “Clinical relevance of mechanisms of antifungal drug resistance in yeasts”. Enfermedades Infecciosas y Microbiología Clínica 9 (2002): 462-469. https://pubmed.ncbi.nlm.nih.gov/12425880/
  56. Campoy S and Adrio JL. “Antifungals”. Biochemical Pharmacology 133 (2017): 86-96. https://pubmed.ncbi.nlm.nih.gov/27884742/
  57. Ghannoum MA and Rice LB. “Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance”. Clinical Microbiology Reviews 4 (1999): 501-517. https://cmr.asm.org/content/12/4/501
  58. Liver Tox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (2012). https://pubmed.ncbi.nlm.nih.gov/31643176/
  59. Kovac M., et al. “Miconazole and nystatin used as topical antifungal drugs interact equally strongly with warfarin”. Journal of Clinical Pharmacy and Therapeutics 1 (2012): 45-48. https://www.researchgate.net/publication/49846869_Miconazole_and_nystatin_used_as_topical_antifungal_drugs_interact_equally_strongly_with_warfarin
  60. Vartak A., et al. “Isolation of a new broad spectrum antifungal polyene from Streptomyces sp. MTCC 5680”. Letters in Applied Microbiology 6 (2014): 591-596. https://pubmed.ncbi.nlm.nih.gov/24517845/
  61. Lakhani P., et al. “Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections”. Journal of Ocular Pharmacology and Therapeutics 1 (2019): 6-22. https://pubmed.ncbi.nlm.nih.gov/30481082/
  62. Dupont B. “Overview of the lipid formulations of amphotericin B”. Journal of Antimicrobial Chemotherapy 1 (2002): 31-36. https://www.researchgate.net/publication/11556620_Overview_of_lipid_formulations_of_amphotericin_B
  63. Kim HJ., et al. “Nystatin-like Pseudonocardia polyene B1, a novel disaccharide-containing antifungal heptaene antibiotic”. Scientific Reports 1 (2018): 13584. https://www.nature.com/articles/s41598-018-31801-y
  64. Sheehan DJ., et al. “Current and emerging azole antifungal agents”. Clinical Microbiology Reviews 1 (1999): 40-79. https://pubmed.ncbi.nlm.nih.gov/9880474/
  65. Perfect JR. “The antifungal pipeline: a reality check”. Nature Reviews Drug Discovery 9 (2017): 603-616. https://pubmed.ncbi.nlm.nih.gov/28496146/
  66. National Center for Biotechnology Information. "PubChem Compound Summary for CID 3823, Ketoconazole" PubChem (2020).
  67. Gupta AK., et al. “New Antifungal Agents and New Formulations Against Dermatophytes”. Mycopathologia1-2 (2017): 127-141. https://pubmed.ncbi.nlm.nih.gov/27502503/
  68. Lipner SR and Scher RK. “Onychomycosis: Treatment and prevention of recurrence”. Journal of the American Academy of Dermatology 4 (2019): 853-867. https://pubmed.ncbi.nlm.nih.gov/29959962/
  69. Ricardo JW and Lipner SR. “Safety of current therapies for onychomycosis”. Expert Opinion on Drug Safety 11 (2020): 1395-1408. https://pubmed.ncbi.nlm.nih.gov/32990062/
  70. Jinna S and Finch J. “Spotlight on tavaborole for the treatment of onychomycosis”. Drug Design, Development and Therapy 9 (2015): 6185-6190. https://pubmed.ncbi.nlm.nih.gov/26640371/
  71. Dias MF., et al. “Treatment of superficial mycoses: review. Part II”. Brazilian Annals of Dermatology 6 (2013): 937-944. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900345/
  72. Dias MF., et al. “Update on therapy for superficial mycoses: review article part I”. Brazilian Annals of Dermatology 5 (2013): 764-774. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798354/
  73. Del Rosso JQ and Bhambri S. “Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis”. The Journal of Clinical and Aesthetic Dermatology 9 (2009): 24-32. https://pubmed.ncbi.nlm.nih.gov/20729956/
  74. Nizoral (Ketoconazole): drug safety communication- potentially fatal liver injury, risk of drug interactions, and adrenal gland problems”. Clinical Infectious Diseases 8 (2013). https://pubmed.ncbi.nlm.nih.gov/24195113/
  75. Greenblatt HK and Greenblatt DJ. “Liver injury associated with ketoconazole: review of the published evidence”. The Journal of Clinical Pharmacology 12 (2014): 1321-1329. https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.400
  76. Hitchcock CA., et al. “Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans”. Biochemical Journal 2 (1990): 475-480. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1131156/
  77. Roemer T and Krysan DJ. “Antifungal drug development: challenges, unmet clinical needs, and new approaches”. Cold Spring Harbor Perspectives in Medicine 5 (2014): a019703. https://pubmed.ncbi.nlm.nih.gov/24789878/
  78. Johnson MD., et al. “Combination antifungal therapy”. Antimicrob Agents Chemother3 (2004): 693-715. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC353116/
  79. Wiederhold NP. “The antifungal arsenal: alternative drugs and future targets". International Journal of Antimicrobial Agents 3 (2018): 333-339. https://pubmed.ncbi.nlm.nih.gov/28890395/
  80. Khadka S., et al. “Clinicomycological Characterization of Superficial Mycoses from a Tertiary Care Hospital in Nepal”. Dermatology Research and Practice (2016): 9509705. https://pubmed.ncbi.nlm.nih.gov/28003819/
  81. Ghannoum M and Isham N. “Fungal nail infections (onychomycosis): a never-ending story?” PLOS Pathogens 6 (2014): e1004105. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1004105
  82. Misner BD. “A novel aromatic oil compound inhibits microbial overgrowth on feet: a case study”. Journal of the International Society of Sports Nutrition 4 (2007): 3. https://jissn.biomedcentral.com/articles/10.1186/1550-2783-4-3
  83. Halteh P., et al. “Over-the-counter and natural remedies for onychomycosis: do they really work?” Cutis 5 (2016): E16-E25. https://pubmed.ncbi.nlm.nih.gov/28040821/
  84. Buck DS., et al. “Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole”. The Journal of Family Practice 6 (1994): 601-605. https://pubmed.ncbi.nlm.nih.gov/8195735/
  85. Carson CF., et al. “Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial and other medicinal properties”. Clinical Microbiology Reviews 1 (2006): 50-62. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1360273/
  86. Karimi A., et al. “Herbal versus synthetic drugs; beliefs and facts”. Journal of Nephropharmacology 1 (2015): 27-30. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297475/
Citation: Kerna NA, Flores JV, Holets HM, Chen MH, Akabike LU, Odugbemi O, Waugh S, Solomon E, Nwokorie U. “The Causes, Consequences, and Cures of Recurrent External Fungal Infections”.EC Clinical and Medical Case Reports 4.1 (2021): 49-59.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before April 26, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk